Clinical trial
A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)
NCT03933449 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 29, 2016
- Completion date
- March 14, 2022
- Enrollment
- 123 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.
esophageal carcinoma, esophagogastric junction carcinoma